fosphenytoin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antiepileptics, hydantoin derivatives 1247 93390-81-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • fosphenytoin
  • cerebyx
  • fosphenytoin sodium
  • fosphenytoin sodium hydrate
  • Molecular weight: 362.28
  • Formula: C16H15N2O6P
  • CLOGP: 0.81
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 3
  • TPSA: 116.17
  • ALOGS: -3.40
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.45 g P

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.06 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.05 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.16 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 142 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
Aug. 5, 1996 FDA PARKE DAVIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 176.55 43.91 192 1926 1044573 62442331
Status epilepticus 171.36 43.91 48 2070 15185 63471719
Multiple-drug resistance 167.53 43.91 38 2080 5132 63481772
Macroglossia 88.45 43.91 16 2102 689 63486215
Drug ineffective for unapproved indication 79.54 43.91 33 2085 34030 63452874
Oropharyngeal oedema 78.29 43.91 13 2105 336 63486568
Laryngeal stenosis 63.65 43.91 13 2105 1065 63485839
Seizure 57.28 43.91 42 2076 132592 63354312
Acquired macroglossia 56.45 43.91 9 2109 179 63486725
Necrotising colitis 52.13 43.91 10 2108 593 63486311
Off label use 51.42 43.91 85 2033 674377 62812527
Drug reaction with eosinophilia and systemic symptoms 50.62 43.91 24 2094 33812 63453092
Hepatic function abnormal 48.49 43.91 24 2094 37118 63449786

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Status epilepticus 143.01 34.92 44 1742 12570 34942575
Drug ineffective 112.86 34.92 126 1660 456625 34498520
Seizure 58.73 34.92 46 1740 104811 34850334
Rhabdomyolysis 54.24 34.92 37 1749 68126 34887019
Nystagmus 43.17 34.92 14 1772 4701 34950444
Cardiac arrest 42.91 34.92 37 1749 96122 34859023
Propofol infusion syndrome 37.93 34.92 9 1777 957 34954188
Multiple-drug resistance 37.79 34.92 13 1773 5226 34949919
Drug ineffective for unapproved indication 37.39 34.92 20 1766 23695 34931450

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Status epilepticus 275.52 32.83 84 3713 24957 79715634
Drug ineffective 254.62 32.83 281 3516 1080632 78659959
Multiple-drug resistance 124.88 32.83 36 3761 8772 79731819
Drug ineffective for unapproved indication 88.85 32.83 45 3752 51193 79689398
Seizure 87.31 32.83 72 3725 188762 79551829
Macroglossia 80.19 32.83 17 3780 1164 79739427
Nystagmus 70.86 32.83 24 3773 9880 79730711
Oropharyngeal oedema 70.46 32.83 13 3784 433 79740158
Drug reaction with eosinophilia and systemic symptoms 68.67 32.83 41 3756 64203 79676388
Hepatic function abnormal 66.27 32.83 42 3755 73065 79667526
Cardiac arrest 66.01 32.83 59 3738 172037 79568554
Laryngeal stenosis 58.90 32.83 13 3784 1075 79739516
Off label use 58.57 32.83 131 3666 907084 78833507
Rhabdomyolysis 55.41 32.83 43 3754 103088 79637503
Bradycardia 54.99 32.83 48 3749 135509 79605082
Acquired macroglossia 51.62 32.83 9 3788 216 79740375
Hypotension 51.30 32.83 82 3715 440235 79300356
Propofol infusion syndrome 51.14 32.83 13 3784 1970 79738621
Blood pressure decreased 43.94 32.83 37 3760 99429 79641162
Anticonvulsant drug level increased 42.79 32.83 12 3785 2641 79737950
Anticonvulsant drug level below therapeutic 42.76 32.83 10 3787 1071 79739520
Electrocardiogram QRS complex prolonged 39.50 32.83 16 3781 10817 79729774
Respiratory depression 38.54 32.83 21 3776 27609 79712982
Fatigue 33.42 32.83 3 3794 929724 78810867

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N03AB05 NERVOUS SYSTEM
ANTIEPILEPTICS
ANTIEPILEPTICS
Hydantoin derivatives
FDA PE N0000008486 Decreased Central Nervous System Disorganized Electrical Activity
MeSH PA D000927 Anticonvulsants
MeSH PA D002317 Cardiovascular Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D026941 Sodium Channel Blockers
FDA EPC N0000175753 Anti-epileptic Agent

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Epilepsy indication 84757009 DOID:1826
Status epilepticus indication 230456007 DOID:1824
Epilepsy characterized by intractable complex partial seizures indication 442481002
Seizures in Neurosurgery indication
Alcoholism contraindication 7200002
Hyperphosphatemia contraindication 20165001 DOID:0050459
Complete atrioventricular block contraindication 27885002
Lymphadenopathy contraindication 30746006
Torsades de pointes contraindication 31722008
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Stokes-Adams syndrome contraindication 46935006
Sinus bradycardia contraindication 49710005
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Leukopenia contraindication 84828003 DOID:615
Kidney disease contraindication 90708001 DOID:557
Prolonged QT interval contraindication 111975006
Hypoalbuminemia contraindication 119247004
Pancytopenia contraindication 127034005 DOID:12450
Second degree atrioventricular block contraindication 195042002
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Granulocytopenic disorder contraindication 417672002
Congenital long QT syndrome contraindication 442917000
HLA-B 1502 Positive Status contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 0.77 acidic
pKa2 5.83 acidic
pKa3 8.0 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium channel protein type 5 subunit alpha Ion channel BLOCKER DRUGBANK CHEMBL

External reference:

IDSource
4024030 VUID
N0000022035 NUI
D02096 KEGG_DRUG
92134-98-0 SECONDARY_CAS_RN
4020973 VANDF
4024030 VANDF
C0244656 UMLSCUI
CHEBI:5165 CHEBI
CHEMBL1201336 ChEMBL_ID
DB01320 DRUGBANK_ID
CHEMBL919 ChEMBL_ID
C043114 MESH_SUPPLEMENTAL_RECORD_UI
56339 PUBCHEM_CID
7190 IUPHAR_LIGAND_ID
6484 INN_ID
B4SF212641 UNII
134860 RXNORM
117573 MMSL
4767 MMSL
6028 MMSL
d04041 MMSL
006181 NDDF
006182 NDDF
108397000 SNOMEDCT_US
372484000 SNOMEDCT_US
386843000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
CEREBYX HUMAN PRESCRIPTION DRUG LABEL 1 0069-5471 INJECTION, SOLUTION 50 mg INTRAVENOUS NDA 28 sections
CEREBYX HUMAN PRESCRIPTION DRUG LABEL 1 0069-5471 INJECTION, SOLUTION 50 mg INTRAVENOUS NDA 28 sections
CEREBYX HUMAN PRESCRIPTION DRUG LABEL 1 0069-5474 INJECTION, SOLUTION 50 mg INTRAVENOUS NDA 28 sections
CEREBYX HUMAN PRESCRIPTION DRUG LABEL 1 0069-5474 INJECTION, SOLUTION 50 mg INTRAVENOUS NDA 28 sections
CEREBYX HUMAN PRESCRIPTION DRUG LABEL 1 0069-6001 INJECTION, SOLUTION 50 mg INTRAVENOUS NDA 27 sections
CEREBYX HUMAN PRESCRIPTION DRUG LABEL 1 0069-6001 INJECTION, SOLUTION 50 mg INTRAVENOUS NDA 27 sections
Fosphenytoin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0143-9782 INJECTION, SOLUTION 50 mg INTRAMUSCULAR ANDA 26 sections
Fosphenytoin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0143-9788 INJECTION, SOLUTION 50 mg INTRAMUSCULAR ANDA 26 sections
Fosphenytoin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0641-6136 INJECTION 50 mg INTRAMUSCULAR ANDA 26 sections
Fosphenytoin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0641-6136 INJECTION 50 mg INTRAMUSCULAR ANDA 26 sections
Fosphenytoin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0641-6137 INJECTION 50 mg INTRAMUSCULAR ANDA 26 sections
Fosphenytoin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0641-6137 INJECTION 50 mg INTRAMUSCULAR ANDA 26 sections
Fosphenytoin HUMAN PRESCRIPTION DRUG LABEL 1 63323-403 INJECTION, SOLUTION 50 mg INTRAMUSCULAR ANDA 32 sections
Fosphenytoin HUMAN PRESCRIPTION DRUG LABEL 1 63323-403 INJECTION, SOLUTION 50 mg INTRAMUSCULAR ANDA 32 sections
FOSPHENYTOIN SODIUM HUMAN PRESCRIPTION DRUG LABEL 1 64679-729 INJECTION 50 mg INTRAMUSCULAR ANDA 25 sections
FOSPHENYTOIN SODIUM HUMAN PRESCRIPTION DRUG LABEL 1 64679-729 INJECTION 50 mg INTRAMUSCULAR ANDA 25 sections
FOSPHENYTOIN SODIUM HUMAN PRESCRIPTION DRUG LABEL 1 64679-730 INJECTION 50 mg INTRAMUSCULAR ANDA 25 sections
FOSPHENYTOIN SODIUM HUMAN PRESCRIPTION DRUG LABEL 1 64679-730 INJECTION 50 mg INTRAMUSCULAR ANDA 25 sections
Fosphenytoin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 65162-998 INJECTION 50 mg INTRAMUSCULAR ANDA 18 sections
Fosphenytoin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 65162-998 INJECTION 50 mg INTRAMUSCULAR ANDA 18 sections
Fosphenytoin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 65162-999 INJECTION 50 mg INTRAMUSCULAR ANDA 18 sections
Fosphenytoin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 65162-999 INJECTION 50 mg INTRAMUSCULAR ANDA 18 sections
Fosphenytoin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 67457-516 INJECTION, SOLUTION 50 mg INTRAVENOUS ANDA 22 sections
Fosphenytoin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 67457-516 INJECTION, SOLUTION 50 mg INTRAVENOUS ANDA 22 sections
Fosphenytoin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 67457-517 INJECTION, SOLUTION 50 mg INTRAVENOUS ANDA 22 sections
Fosphenytoin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 67457-517 INJECTION, SOLUTION 50 mg INTRAVENOUS ANDA 22 sections
Fosphenytoin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 70121-1381 INJECTION 50 mg INTRAMUSCULAR ANDA 26 sections
Fosphenytoin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 70121-1381 INJECTION 50 mg INTRAMUSCULAR ANDA 26 sections
Fosphenytoin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 70121-1390 INJECTION 50 mg INTRAMUSCULAR ANDA 26 sections
Fosphenytoin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 70121-1390 INJECTION 50 mg INTRAMUSCULAR ANDA 26 sections